Published in J Card Fail on April 01, 2004
Changes in diastolic dysfunction in diabetes mellitus over time. Am J Cardiol (2009) 1.21
Development and validation of a risk score for hospitalization for heart failure in patients with Type 2 diabetes mellitus. Cardiovasc Diabetol (2008) 0.94
Diminished renal function and the incidence of heart failure. Curr Cardiol Rev (2009) 0.77
Type 2 Diabetes and Heart Failure: Challenges and Solutions. Curr Cardiol Rev (2016) 0.75
Renal failure in cirrhosis. N Engl J Med (2009) 4.46
Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Am J Med (2013) 4.34
Reduction in acute myocardial infarction mortality in the United States: risk-standardized mortality rates from 1995-2006. JAMA (2009) 4.24
Reduction in the incidence of acute myocardial infarction associated with a citywide smoking ordinance. Circulation (2006) 3.99
Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol (2010) 3.64
Decision making in advanced heart failure: a scientific statement from the American Heart Association. Circulation (2012) 3.61
Diagnosis and treatment of acute tubular necrosis. Ann Intern Med (2002) 3.33
Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med (2007) 3.22
Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure. Am Heart J (2003) 3.11
Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int (2002) 3.10
State of the science: promoting self-care in persons with heart failure: a scientific statement from the American Heart Association. Circulation (2009) 3.05
Race, quality of care, and outcomes of elderly patients hospitalized with heart failure. JAMA (2003) 2.77
Admission glucose and mortality in elderly patients hospitalized with acute myocardial infarction: implications for patients with and without recognized diabetes. Circulation (2005) 2.69
Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol (2004) 2.69
National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction. Circulation (2004) 2.46
Gender, age, and heart failure with preserved left ventricular systolic function. J Am Coll Cardiol (2003) 2.46
Thresholds in the relationship between mortality and left ventricular hypertrophy defined by electrocardiography. J Electrocardiol (2008) 2.29
Interstitial vascular rarefaction and reduced VEGF-A expression in human diabetic nephropathy. J Am Soc Nephrol (2007) 2.20
Angiogenic growth factors correlate with disease severity in young patients with autosomal dominant polycystic kidney disease. Kidney Int (2010) 2.12
Modifier genes play a significant role in the phenotypic expression of PKD1. Kidney Int (2005) 2.03
Prospective change in renal volume and function in children with ADPKD. Clin J Am Soc Nephrol (2009) 2.02
Health status identifies heart failure outpatients at risk for hospitalization or death. J Am Coll Cardiol (2006) 1.98
Relationship between renal volume growth and renal function in autosomal dominant polycystic kidney disease: a longitudinal study. Am J Kidney Dis (2002) 1.92
Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial. Eur Heart J (2011) 1.88
Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation (2005) 1.83
Glomerular hyperfiltration: definitions, mechanisms and clinical implications. Nat Rev Nephrol (2012) 1.80
Regional differences in process of care and outcomes for older acute myocardial infarction patients in the United States and Ontario, Canada. Circulation (2006) 1.78
Symptoms, depression, and quality of life in patients with heart failure. J Card Fail (2007) 1.77
Autosomal-dominant polycystic kidney disease in infancy and childhood: progression and outcome. Kidney Int (2005) 1.72
Presence of de novo mutations in autosomal dominant polycystic kidney disease patients without family history. Am J Kidney Dis (2008) 1.71
Socioeconomic status, treatment, and outcomes among elderly patients hospitalized with heart failure: findings from the National Heart Failure Project. Am Heart J (2006) 1.69
Clinicians' implicit ethnic/racial bias and perceptions of care among Black and Latino patients. Ann Fam Med (2013) 1.67
Angiotensin blockade in late autosomal dominant polycystic kidney disease. N Engl J Med (2014) 1.64
Best paper of the 1980s: National Institutes of Health Consensus Development Conference Statement: geriatric assessment methods for clinical decision-making. 1988. J Am Geriatr Soc (2003) 1.64
Glomerular hyperfiltration and renal progression in children with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol (2011) 1.62
Symptom burden, depression, and spiritual well-being: a comparison of heart failure and advanced cancer patients. J Gen Intern Med (2009) 1.62
Trends in acute myocardial infarction in 4 US states between 1992 and 2001: clinical characteristics, quality of care, and outcomes. Circulation (2006) 1.61
Integrating palliative care into heart failure care. Arch Intern Med (2005) 1.60
The HALT polycystic kidney disease trials: design and implementation. Clin J Am Soc Nephrol (2010) 1.59
The relationship between B-type natriuretic peptide and health status in patients with heart failure. J Card Fail (2005) 1.58
Molecular mechanisms of antidiuretic effect of oxytocin. J Am Soc Nephrol (2007) 1.55
Earlier diagnosis of autosomal dominant polycystic kidney disease: importance of family history and implications for cardiovascular and renal complications. Am J Kidney Dis (2005) 1.55
Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. Eur J Endocrinol (2011) 1.54
Anemia and outcomes in patients with heart failure: a study from the National Heart Care Project. Arch Intern Med (2005) 1.54
Cardiorenal syndrome in acute decompensated heart failure. Clin J Am Soc Nephrol (2009) 1.50
Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes. Am J Hypertens (2006) 1.47
Physician specialty and mortality among elderly patients hospitalized with heart failure. Am J Med (2005) 1.45
Blood urea nitrogen and serum creatinine: not married in heart failure. Circ Heart Fail (2008) 1.45
Regional variations in racial differences in the treatment of elderly patients hospitalized with acute myocardial infarction. Am J Med (2004) 1.44
Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med (2015) 1.40
Association of door-to-balloon time and mortality in patients > or =65 years with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am J Cardiol (2009) 1.40
Pathophysiological roles of arginine vasopressin and aquaporin-2 in impaired water excretion. Clin Endocrinol (Oxf) (2003) 1.39
Impact of medication nonadherence on hospitalizations and mortality in heart failure. J Card Fail (2011) 1.39
Cardiovascular abnormalities in autosomal-dominant polycystic kidney disease. Nat Rev Nephrol (2009) 1.36
Discontinuation of antihyperglycemic therapy and clinical outcomes after acute myocardial infarction in older patients with diabetes. Circ Cardiovasc Qual Outcomes (2010) 1.35
Changing referral characteristics of patients with autosomal dominant polycystic kidney disease. Am J Med (2013) 1.34
The complexity and cost of drug regimens of older patients hospitalized with heart failure in the United States, 1998-2001. Arch Intern Med (2005) 1.32
Sociodemographic and clinical characteristics are not clinically useful predictors of refill adherence in patients with hypertension. Circ Cardiovasc Qual Outcomes (2009) 1.31
Does 'asymptomatic hyponatremia' exist? Nat Rev Nephrol (2010) 1.30
Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes. Circulation (2003) 1.28
Interaction among nitric oxide, reactive oxygen species, and antioxidants during endotoxemia-related acute renal failure. Am J Physiol Renal Physiol (2003) 1.28
Race and renal impairment in heart failure: mortality in blacks versus whites. Circulation (2005) 1.28
Age, functional capacity, and health-related quality of life in patients with heart failure. J Card Fail (2004) 1.27
Molecular mechanisms of impaired urinary concentrating ability in glucocorticoid-deficient rats. J Am Soc Nephrol (2005) 1.27
Endotoxemic acute renal failure is attenuated in caspase-1-deficient mice. Am J Physiol Renal Physiol (2005) 1.26
Social Determinants of Risk and Outcomes for Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation (2015) 1.25
Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998-2001. Circulation (2005) 1.24
Appropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trial. Nat Clin Pract Nephrol (2007) 1.22
Increased left ventricular mass in children with autosomal dominant polycystic kidney disease and borderline hypertension. Kidney Int (2008) 1.21
Caspase inhibition reduces tubular apoptosis and proliferation and slows disease progression in polycystic kidney disease. Proc Natl Acad Sci U S A (2005) 1.20
Care by cell phone: text messaging for chronic disease management. Am J Manag Care (2012) 1.20
Magnetic resonance imaging of kidney and cyst volume in children with ADPKD. Clin J Am Soc Nephrol (2010) 1.20
Genotype-phenotype correlation in X-linked Alport syndrome. J Am Soc Nephrol (2010) 1.19
Serum phosphorus and cardiovascular mortality in type 2 diabetes. Am J Med (2009) 1.19
Elevated admission glucose and mortality in elderly patients hospitalized with heart failure. Circulation (2009) 1.19
Serum urea nitrogen, creatinine, and estimators of renal function: mortality in older patients with cardiovascular disease. Arch Intern Med (2006) 1.18
An investigation of associations between clinicians' ethnic or racial bias and hypertension treatment, medication adherence and blood pressure control. J Gen Intern Med (2014) 1.18
Assessment of biases against Latinos and African Americans among primary care providers and community members. Am J Public Health (2012) 1.18
Testing electronic algorithms to create disease registries in a safety net system. J Health Care Poor Underserved (2008) 1.17
Incident chronic kidney disease and the rate of kidney function decline in individuals with hypertension. Nephrol Dial Transplant (2009) 1.17
Metformin and thiazolidinedione use in Medicare patients with heart failure. JAMA (2003) 1.15
Hypertonicity-induced aquaporin-1 (AQP1) expression is mediated by the activation of MAPK pathways and hypertonicity-responsive element in the AQP1 gene. J Biol Chem (2003) 1.14
Analysis of baseline parameters in the HALT polycystic kidney disease trials. Kidney Int (2011) 1.13
Improving the outcomes of heart failure care: putting technology second. J Am Coll Cardiol (2005) 1.13
Polycystic liver: clinical characteristics of patients with isolated polycystic liver disease compared with patients with polycystic liver and autosomal dominant polycystic kidney disease. Liver Int (2007) 1.11
Renal dysfunction in allogeneic hematopoietic cell transplantation. Kidney Int (2002) 1.11
cAMP regulates vasopressin-induced AQP2 expression via protein kinase A-independent pathway. Biochim Biophys Acta (2006) 1.10
Effect of statin and angiotensin-converting enzyme inhibition on structural and hemodynamic alterations in autosomal dominant polycystic kidney disease model. Am J Physiol Renal Physiol (2007) 1.09
Difficulty taking medications, depression, and health status in heart failure patients. J Card Fail (2006) 1.09
The burden of chronic congestive heart failure in older persons: magnitude and implications for policy and research. Heart Fail Rev (2002) 1.09
Unconscious (implicit) bias and health disparities: where do we go from here? Perm J (2011) 1.07
Characteristics of hypertension in young adults with autosomal dominant polycystic kidney disease compared with the general U.S. population. Am J Hypertens (2004) 1.07
A multimodal blood pressure control intervention in 3 healthcare systems. Am J Manag Care (2011) 1.07
Prediction of cardiovascular death in racial/ethnic minorities using Framingham risk factors. Circ Cardiovasc Qual Outcomes (2010) 1.07